You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.
News items for the in vitro diagnostics industry for the week of June 8, 2020.
Hologic received clearance for a change to a probe reagent in the Aptima Combo 2 assay to detect variants of Chlamydia trachomatis that have emerged recently.
The test uses a proprietary at-home PCR nasal swab test with a turnaround time of 24 hours and is authorized for use by at-risk people.
The firm said it has begun distributing the Aptima SARS-CoV-2 test and expects to produce an average of 1 million per week.
Only 2.5 percent of Americans have been tested for COVID-19, even as industry scrambles to increase testing capacity and a second wave of cases may hit in the fall.
Starting in late May, Hologic expects to begin producing at least 1 million Aptima SARS-CoV-2 assays per week, BARDA noted.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.
In parallel with the release of its financial results, Hologic announced that it plans to launch a new Aptima molecular assay to detect the SARS-CoV-2 virus that will run on its Panther system.
Abbott's RealTime CT/NG assay is currently only cleared by the US Food and Drug Administration for use with urogenital samples.